Prevents rejection in renal homotransplantation. ANDA 208687, held by Alkem Labs Ltd. Azathioprine.
As of Nov 16, 2026, ANDA 208687 (Azathioprine), held by Alkem Labs Ltd, was first approved by FDA on Mar 27, 2020, with 1 approved supplement and 0 published complete response letters.
INDICATIONS & USAGE Azathioprine is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms. Renal Homotransplantation: Azathioprine is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2020 | Original application | Approved | None posted |
| Azathioprine25MG · tablet;oral | Azathioprine | Rx |
| Azathioprine50MG · tablet;oral | Azathioprine | Rx |
| Azathioprine75MG · tablet;oral | Azathioprine | Rx |
| Azathioprine100MG · tablet;oral | Azathioprine | Rx |
| Jun 13, 2025 | Supplement 6Labeling · Standard review | Approved | None posted |
| Mar 27, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters